CCL2 and atherosclerosis: Another study that used a low dose of rivaroxaban (28.5 ng/mL in plasma) was able to attenuate progression of atherosclerosis by roughly 25%, as well as reduced inflammation, as reflected by decreased IL-1β, MCP-1, and TNF-α mRNA and protein levels17.